Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Unitaid"

12 News Found

Shionogi and MPP sign licence agreement for COVID-19 oral antiviral treatment
News | October 04, 2022

Shionogi and MPP sign licence agreement for COVID-19 oral antiviral treatment

Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.

Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for HIV in South Africa
Public Health | June 15, 2022

Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for HIV in South Africa

This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.

Latest Stories

Lupin receives positive CHMP opinion for biosimilar Ranibizumab

Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year

AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging